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methods commonly rely on expression of epithelial cell adhe-
sion molecule (EpCAM), a surface protein, to isolate CTCs and 
typically require low fl ow rates (1–3 mL h −1 ) to ensure that CTCs 
have suffi cient time to be immobilized by functionalized sur-
faces. [ 5,6 ] Issues concerning cell release of the immobilized cells 
also arise. [ 7 ] In contrast label-free isolation does not rely on spe-
cifi c biomarkers but instead on inherent CTC properties such as 
size, deformability, or dielectric susceptibility. Size-based sorting 
usually offers higher throughputs since bulk sorting is used. 
 Moreover, since the discovery of microfl uidic inertial size-
based sorting, it was reported that enhanced sorting is achieved 
by incorporating curvature into microfl uidic channels. Curva-
ture introduces Dean forces that augment the inertial forces 
acting on particles under fl ow and can generally be performed 
with high fl ow rates ranging from 500 to 2000 µL min −1 , while 
maintaining typical microfl uidic dimensions (see Section S2, 
Supporting Information). [ 8–11 ] Whereas label-free methods are 
rapid, specifi city is lacking and operation is limited by overall 
high blood cell counts. The recently reported CTC iChip uses 
hydrodynamic, inertial, and magnetic sorting to isolate CTCs 
from whole blood. [ 12 ] A throughput of 8 mL h −1 using positive 
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 Not surprisingly CTC biology has sparked burgeoning interest 
within recent years because of the postulated role of these 
rare cells in metastasis. CTCs initiate from the primary tumor 
and migrate in the blood and then occupy a secondary site to 
subsequently metastasize. [ 1 ] They inherently carry information 
about the tumor that could be useful for understanding metas-
tasis and developing novel therapeutics to more effectively treat 
these potentially harmful cells. Since CTCs can be isolated 
from a simple blood draw, they can be routinely used to yield 
insight into tumor pathology and treatment response without 
invasive procedures. [ 2 ] 
 However, CTC detection and isolation from whole blood 
is quite challenging. First, CTCs are rare; there may be only 
one CTC in 7.5 mL of blood containing billions of blood cells. 
Second, there is limited knowledge of specifi c CTC markers, 
due in part to CTC heterogeneity such that they vary pheno-
typically and genotypically among patients. [ 3 ] Considering CTC 
rarity and heterogeneity, engineering a device to isolate them 
from blood presents an interesting, important challenge. 
 Two chief approaches used for CTC collection are immunoaf-
fi nity capture and label free, size-based fi ltering. [ 4 ] Immune-based 
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immunomagnetic selection, with an average of 1500 contami-
nating white blood cells (WBCs) from 1 mL whole blood were 
achieved. Purity was affected by non-specifi c WBC labeling with 
magnetic beads. 
 We report the development of an ultra-specifi c microfl uidic 
device that combines inertial microfl uidics and immuno-
magnetism in a uniquely designed workfl ow that minimizes non-
specifi c cell labeling for effi cient isolation of CTCs from whole 
blood with ultra-high CTC purity rates and high throughput. We 
hypothesized that beginning the CTC isolation process by rapid 
inertial pre-sorting would greatly reduce the number of unwanted 
cells from whole blood so that micrometer-scale, on-chip pas-
sive mixing and brief on-chip incubation would facilitate spe-
cifi c, extensive CTC magnetic bead labeling. Then, ultra-specifi c 
sorting of the pre-enriched magnetized CTCs could be achieved 
via magnetic sorting. Specifi cally, the microfl uidic design would 
allow for whole blood to be processed rapidly yet meticulously on 
a single chip, requiring no blood preparation or long incubation 
times. This would minimize the extent of non-specifi c binding to 
promote CTC isolation purity. Unlike most other platforms, our 
approach negates bulk CTC labeling and instead uses on-chip 
CTC-bead labeling which improves the labeling chances of target 
cell, allowing magnetization and successful isolation from blood 
samples (see Table S1, Supporting Information). 
 The functionality of each component is illustrated in  Figure  1 , 
showing cell distribution throughout the device. The fi rst step of 
inertial sorting involves fl owing whole blood into one inlet and 
phosphate buffered saline (PBS) into the other inlet of the spiral 
module. The use of two differently sized syringes biases the two 
fl ows such that whole blood fl ows at ≈400 µL min −1 , while buffer 
fl ows at 1200 µL min −1 . By biasing the fl ow the higher buffer 
fl ow rate readily stabilizes fl ow prior to the blood sample intro-
duction so that no blood sample is wasted initially due to the fl ow 
stabilization process. Concurrently, the blood sample is diluted 
so that the effect of waste cells on cancer cell fl ow dynamics, as 
well as on purity and recoveries is effectively reduced. 
 Next, the CTC-enriched stream which leaves the inertial 
sorter at the innermost outlet, enters the passive mixer where 
it mixes with EpCAM coated magnetic beads infused at 100 µL 
min −1 . After mixing, 5 min on-chip incubation is carried out 
in four reservoirs to promote extensive magnetic bead-CTC 
labeling via antibody–antigen interactions. 
 To achieve immediate CTC magnetic sorting after incubation, 
the reservoir inlet is gently and gradually pressurized with an air-
fi lled syringe so that the mixture can fl ow out of the reservoirs in a 
controlled manner. The mixture drains directly into the magnetic 
sorter between two buffer streams and permanent magnets lined 
along the magnetic sorter defl ect the magnetically labeled CTCs 
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 Figure 1.  Design of ultra-specifi c CTC isolation platform. A) Schematic showing inertial sorting, passive mixing with incubation and magnetic sorting. 
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away from unlabeled blood cells to the CTC collection outlet. The 
fi nal collection is a highly enriched suspension of viable CTCs. 
 The inertial sorter separates larger particles (15–20 µm) from 
smaller particles (7–10 µm).  Figure  2 A shows the fabricated 
polydimethylsiloxane (PDMS) device, Figure  2 B illustrates the 
arrangement of cancer cells (green) versus WBCs (blue) at the 
outlet of the sorter, and Figure  2 C demonstrates how the poly-
styrene particles (20 µm (green), 15 µm (blue), 7 µm (orange)) 
separate into distinct, focused streams at the outlets of the spiral 
channel. Similarly in Figure  2 D PANC-1 cancer cells (green 
streak) focus to the innermost outlet and WBCs (blue streak) 
focus to the second outlet. Figure  2 E shows how the larger 
PANC-1 cells (indicated by red arrows) spiked into diluted blood 
focus to the innermost outlet amidst the other blood cells. 
 To quantitatively evaluate inertial sorting PANC-1 cells and 
WBCs were spiked into PBS and processed through the module. 
The effl uents from each outlet were collected and analyzed for 
cell counts. Notably, Figure  2 F shows 90.95% ± 3.61 of cancer 
cells were collected in the desired outlet. Whole blood was rou-
tinely diluted by ×10 for blood-spiked experiments to facilitate 
conditions amenable to microscope visuali zing. Figure  2 G 
shows cell distribution in the four outlets after repeating the 
experiments in diluted blood. Results consistent with PBS-spiked 
experiments were achieved such that 91.99% ± 4.94 of cancer 
cells were enriched in the innermost spiral outlet. The spiral 
design was optimized as a stand-alone device and subsequently, 
the three waste outlets were re-designed to allow for resistance-
matching once it was connected within the fully integrated 
system (see Figure S1 and Table S2, Supporting Information). 
 The passive mixer facilitates mixing of EpCAM magnetic 
beads with the CTC-rich effl uent from the spiral sorter so that 
magnetic beads bind to cancer cells through antibody–antigen 
complexes. Mixing occurs after inertial whole blood pre-sorting 
to increase the chances of bead-cancer cell interactions, which 
economizes on the quantity of required antibodies. Additionally, 
mixing occurs at length-scales comparable to cancer cell sizes 
thus promoting effi cient bead-CTC labeling compared to bulk 
labeling. Because both viscous and inertial forces are appreci-
able in this range of Re, “secondary fl ows” arise in both axial and 
radial directions thus increasing the interfacial area over which 
diffusion and mixing occur (see Section S3, Supporting Informa-
tion). [ 13 ] Furthermore, the short mixing time required decreases 
the likelihood of nonspecifi c binding with non-target cells. 
 Using fl ow rates of 10–100 µL min −1 , mixers were fi rst evalu-
ated by testing the distance along various designs required for 
two distinct streams of yellow- and blue-dyed PBS to become 
one well-mixed green stream (see Figure S2, Supporting Infor-
mation). The highly compact selected mixer design enabled 
fl uids to completely mix by the third channel segment, after 
≈4 cm footprint. Next cancer cell labeling with EpCAM beads 
was examined through static experiments (PANC-1 cells and 
EpCAM beads in an Eppendorf tube) and on-chip experi-
ments (on-chip passive mixing of cells and beads subsequently 
fl owed into reservoirs). Calculations demonstrate that for a 
20 µm cell to experience a suffi cient magnetic force to pull it 
in the direction perpendicular to fl ow and therefore sort it, less 
than 1/3 bead coverage is required (see Section S4, Supporting 
Information). For four incubation time points (5, 10, 15, and 30 
min), labeling was evaluated by immediately imaging the mixed 
effl uent to quantify beads attached to cells. Cells were character-
ized as having no coverage, <1/3, 1/3–2/3, and >2/3 coverage 
(see Figure S3, Supporting Information). In static conditions 
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 Figure 2.  Optimizing inertial sorter module. A) PDMS device. B) Larger CTCs (green) go to innermost outlet channel. C) Fluorescent beads, D) fl uorescent 
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15 min incubation allowed at least 1/3 coverage on only 85% 
of cells (Figure S6, Supporting Information). Conversely, when 
cells diluted in blood and beads were mixed on-chip at 100 µL 
min −1 and allowed 5 min incubation in the reservoirs, >92% of 
the cells demonstrated over 1/3 coverage. Thus, 5 min of incu-
bation was determined to be optimal for on-chip labeling. Not 
only do the reservoirs facilitate on-chip incubation for extensive 
cancer cell bead coverage, yet they enable a seamless switch of 
fl ow rates from 1200 to 50 µL min −1 , which in turn facilitates 
sensitive, thorough magnetic sorting of magnetized cancer cells. 
 The magnetic sorter has three inlets consisting of two 
outer buffer streams and one middle sample stream that fl ow 
in a 250 µm wide channel and allows for further continuous 
on-chip cell sorting. [ 14 ] Confi ning the sample stream in this 
manner ultimately provides effi cient magnetized CTC sorting 
from contaminating cells by ensuring that only magnetized 
cells are attracted into the collection outlet. The sorter outlet is 
split into two channels, with a smaller collection (35 µm) and 
a larger waste (65 µm) channel. Permanent magnets (500 mT, 
K&J Magnetics) aligned end-to-end, are positioned parallel to 
the main channel with a 1 mm PDMS separation gap between 
the channel and the magnets. The sample continuously fl ows 
through the sorter at 50 µL min −1 so that cells with as few 
as 1/3 surface bead coverage are defl ected into the collection 
channel. Waste cells continue uninterrupted to the waste outlet. 
 In determining the appropriate magnetic sorting fl ow rates, 
PANC-1 cells pre-labeled with magnetic beads were fl owed 
through the sorter at test rates of 25–100 µL min −1 , with top 
(farther from magnet) buffer streams of 15–50 µL min −1 and 
bottom (closer to magnet) buffer streams of 25–75 µL min −1 . 
Biasing the fl ow rates was readily achieved by using two 
different size syringes at a fi xed syringe drive setting so that 
the top and bottom streams could simultaneously fl ow at two 
different fl ow rates. Notably, biasing the fl ow in this manner 
signifi cantly improved magnetic sorting by allowing magnet-
ized cells to fl ow slower to maximize magnetic trapping and 
to enhance separation distance of waste cells from the collec-
tion channel (see Video S1, Supporting Information). Using 
75 µL min −1 bottom, 25 µL min −1 top buffer, and 50 µL min −1 
fl ow rates, results show that for blood spiked tests, WBC con-
tamination was 2.28% ± 0.68 and recovery effi ciency was 
94.60% ± 1.48. Of note, the few PANC-1 cells in the waste were 
poorly labeled and so not expected to be magnetically sorted 
(Figure S6, Supporting Information). 
 To establish the proof-of-concept of the device, 1 mL whole 
blood was routinely processed. PANC-1 cells spiked at 100 and 
1000 cells mL −1 were used to evaluate device performance with 
cancer cells. Results demonstrate that effi ciency of PANC-1 col-
lection was nearly 90% ( Figure  3 C). For both cases, contamina-
tion ranged from 82 to 801 WBCs mL −1 (Figure  3 D), resulting 
in purities of up to 75%. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was 
used to assess isolated PANC-1 cell viability which revealed that 
cells processed through the integrated system had viability rates 
comparable to that of the unprocessed control cells thus sup-
porting the feasibility of culturing the collected cells (Figure S8, 
Supporting Information). Also, in consideration of developing 
a point-of-care diagnostic device, the antibody-labeled beads 
were tested and demonstrated stability in cancer cell labeling 
even after 100 d (see Section S7, Supporting Information). The 
unprecedented purity rates achieved by the device supersede 
some of the other reported technologies including GEDI (68%), 
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 Figure 3.  Integrated device operation. A) Magnetic sorter outlets show highly enriched cancer cells separating from waste cells. B) Immunofl uores-
cence staining used in identifying cancer cells (PANC-1) and WBCs with inset of magnetically labeled cancer cell (10 µm scale bar). C) Recovery of 
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herringbone (14%), iChip (1500 WBCs mL −1 ), and the CTC 
chip (9%) [ 5,12,15,16 ] and facilitates CTC molecular profi ling. 
 14 metastatic or locally advanced PDAC patient samples 
and four healthy controls were processed through the device 
( Figure  4 A). Up to 1.4 mL of whole blood from each patient 
was processed and CTCs were identifi ed via fl uorescent immu-
nostaining for CK+/DAPI+/CD45−. Additional confi rmation 
of an epithelial cell type was garnered by brightfi eld images 
showing bound EpCAM magnetic beads on the cells. WBCs 
were identifi ed as CK−/DAPI+/CD45+.  Figures  4 D and  5 E 
are representative images of fl uorescently labeled CTCs and 
WBCs, respectively. Samples were enumerated and CTC purity 
percentages are as reported in  Figure  5 C. The corresponding 
patient clinical data are shown in Table S3 (Supporting Infor-
mation). For all 14 patients, CTCs were isolated with counts 
ranging from 14 to 938 CTCs mL −1 which was higher than 
the average 3 CTCs mL −1 for healthy controls. Notably, CTCs 
have been recovered from patient blood with signifi cant deple-
tion, on the order of 10 6 WBCs with average CTC purity being 
82.5% ± 23.5. 
 Although magnetic sorting is the rate limiting process, 
occurring at 50 µL min −1 , it can easily be multiplexed. Using 
parallel sorters ( n = 8) on a single chip, the entire process can 
be maintained at 400 µL min −1 , yielding an overall processing 
rate of greater than 20 mL h −1 and still yield unprecedented 
purities of greater than 80%. 
 MiRNAs are important regulators of cancer cell proper-
ties; however, they have been, in general, understudied in the 
context of CTCs. Currently, the relatively low purity rates prof-
fered by most CTC isolation technologies limit specifi city in 
genomic characterizing. The high CTC purities of our device 
enable CTC-specifi c miRNA profi ling. Accordingly we profi led 
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 Figure 4.  Processing PDAC samples. A) Cell counts of CTCs in 1 mL of patient blood. Percent purities are indicated. B) Corresponding WBCs for the 
same samples. C) Log exp values for ten highest expressed miRNAs. D) Fluorescent and brightfi eld image of CTCs and E) WBCs identifi ed through 
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372 miRNAs in CTC enriched samples from two locally 
advanced PDAC patients alongside a healthy control individual. 
 Of the 372 miRNAs profi led, 106 miRs demonstrated abun-
dance in expression in both samples compared to the healthy 
control. 81 miRs had low expression and were categorized as 
not reliably detected. Interestingly, several miRs previously 
reported as associated with PDAC including, miR-221-3p, 210, 
-23a-3p, -143-3p, and -21-5p were among those highly expressed 
 Figure 5.  Messenger RNA profi ling of CTC enriched PDAC samples from three borderline (B) and two locally advanced (L) patients as well as three 
metastatic patients (M). A) Heat map plot reveal that two metastatic profi les cluster together as a separate group from others excluding one outlier 
patient. Seven genes (green box) distinguish between the two groups. B) Log fold increase plot shows mRNAs increased in borderline versus metastatic 
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in the CTC samples (Figure  4 C). [ 17–20 ] Additionally, based on 
pathway analysis, the top network functions enriched in the 
profi les were for cancer and organismal injury and abnormali-
ties. Pathways involving Smad2/3 and MAP2K1/2 were impli-
cated in PDAC CTC biology (see Figure S9, Supporting Infor-
mation). Moreover, for the fi rst time we report that PDAC CTC 
miRNA profi ling revealed a trend toward high expression of 
miRs 17-5p, 19b-3p, 320b, and let7a-5p. Also, miR-96-3p, 216b, 
155-5p, 212-3p, and -31-5p which demonstrated decreased 
expression have been previously reported to exhibit down regu-
lation in pancreatic cancer. [ 17,18 ] 
 To further demonstrate the potential of the integrated device 
in allowing sensitive molecular interrogation of CTC samples 
subsequent to CTC isolation, mRNA profi ling was carried 
out on eight additional patient samples. Of these, three were 
categorized as borderline and two as locally advanced while 
three were metastatic. When metastatic profi les were grouped 
against other patients, as seen in Figure  5 A, all borderline pro-
fi les clustered closely while two of three metastatic cases clus-
tered apart from all other profi les. Moreover, seven mRNAs 
Zeb1, KLF4, cMYC, BRCA1, HER2, CD3D, and HPRT1 
levels (indicated by the green box in Figure  5 A) were able to 
distinguish among the two groups. SPARC was also higher-
expressed in the metastatic group (LogFC = 4.7,  p = 0.037). 
Specifi cally, Zeb1 (LogFC = 11.6,  p = 0.037) has shown to be an 
independent predictor of mortality in pancreatic cancer while 
the cause of overexpression of cMYC (LogFC = 9.9,  p = 0.037) 
in pancreatic cancers has been previously studied. [ 21,22 ] The 
role of KLF4 (LogFC = 11.6,  p = 0.037) as both as a tumor sup-
pressor and an oncogene in cancer progression was previously 
reported. [ 23 ] Interestingly, BRCA1 (LogFC = 10.9,  p = 0.037) 
was reported to be down regulated in cases of pancreatitis and 
sporadic PDAC. [ 24 ] Additionally, the results of HER2 amplifi ca-
tion (LogFC = 10.1,  p = 0.037) among PDAC patients showed 
potential for therapeutic endeavors. [ 25 ] Aberrantly high expres-
sion of SPARC (LogFC = 4.7,  p = 0.037) in pancreatic CTCs 
was also observed in both mouse and human samples. [ 26 ] 
Taken together, the corroboration of reported studies by the 
results of CTC molecular profi ling enriched by the described 
device show promise in its use to ascertain information that 
may be specifi c to CTCs. 
 In summary, the integrated microfl uidic device described 
is capable of generating signifi cantly enriched, viable CTCs 
which enable CTC miRNA and mRNA analysis. The device 
uses inertial sorting to perform rapid pre-sorting of the orig-
inal sample which signifi cantly reduces the amount of sample, 
thus reducing the overall time required for processing. On-
chip magnetic labeling allows for very sensitive CTC-bead tag-
ging in the absence of the majority of blood cells and reduces 
non-specifi c binding. By multiplexing the magnetic sorter 
module, the device can process up to 10 mL of blood in 1 h 
and is a closed device requiring limited user involvement. 
Ultra-pure CTC-specifi c RNA profi ling revealed abundance 
in expression of miRs 17-5p, 19b-3p, 320b, and let7a-5p along 
with mRNAs Zeb1, KLF4, cMYC, BRCA1, HER2, CD3D, and 
HPRT1 in PDAC derived CTCs. The platform presented here 
should enable more studies of CTC RNA expression which 
can in turn, help to identify their putative roles in cancer 
metastasis. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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